Virtual Library
Start Your Search
Asmita Rayamajhi
Author of
-
+
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.01-30 - Clinico-Pathological Profile of Adenocarcinoma of the Lung – A Prospective Study in a Nepalese Population (Now Available) (ID 722)
08:00 - 18:00 | Author(s): Asmita Rayamajhi
- Abstract
Background
Lung cancer represents the most common cause of cancer related mortality in developing countries including Nepal where patients (pts) often present in advanced stage. The purpose of this study was to determine the incidence and clinico-pathological profile of pts with adenocarcinoma of the lung (ACL) presented to a tertiary care center of Nepal.
Method
An IRB approved prospective study was conducted in pts with ACL over a period of 15 months from April 2017 to July 2018 at a tertiary care center, Bir Hospital, Kathmandu. Demographic data, history of smoking, histological type, presence and type of epidermal growth factor receptor (EGFR) mutations were studied. EGFR-analysis was performed using TheraScreen EGFR mutation kit.
Result
A total of 253 pts were diagnosed with lung cancer in the period. Of the 83 (33%) diagnosed with ACL, 45 (54%) were males and 38 (46%) females. The mean age at diagnosis was 59.4 years, and 74 (89%) were in stage III/IV. Forty eight (58%) pts were smoker of whom 30 (63%) pts had less than 10 pack years. Sixty one percent (61%) were illiterate. Eighteen (22%) pts had wrongly received anti-tuberculosis treatment before the diagnosis of ACL was made. All ACL pts were tested for EGFR-mutations which were found in 24 (29%) pts, the most common mutation being exon 21 (L858R) (42%) followed by exon 19 deletion (38%). Exon 18 and exon 20 (T790M) mutation were found in 2 pts (8%) each. One pt had dual mutation in exon 20 (T790M) and exon 21 (L858R).
Conclusion
The frequency of EGFR-mutations in ACL in this Nepalese cohort was lower than in Eastern Asian studies, but higher than in western population. EGFR mutation testing of ACL has to be encouraged in developing countries like Nepal as presence of these mutations predict durable response to oral tyrosine kinase inhibitors. Interestingly, lung cancer is often mistreated as tuberculosis leading to delay in diagnosis and treatment.
